In Santa Rosa, California, a two-building campus along Unocal Place has been a feature of the local skyline for almost thirty years. Engineers, clinical researchers, and support personnel who developed careers within a company that manufactures pacemakers, heart valves, and cardiovascular stents were housed in the Fountaingrove complex, which is situated against the gentle hills of Sonoma County wine country. Medtronic informed all 370 of them in May 2026 that they would lose their jobs by spring 2028, along with the campus itself. Internally, it was referred to as a “difficult but strategic decision.” From the outside, it appeared to be nothing new for the North Bay.
Anyone familiar with the economic history of the area will quickly notice a pattern in Medtronic’s departure from Santa Rosa. During the telecom boom, Hewlett-Packard established itself here. Agilent followed. Since then, the majority of those well-known figures have either vanished or become much less prominent. Every exit left a neighborhood slightly quieter than before, and they all used the same cautious language regarding global alignment and portfolio optimization. The North Bay is constantly questioning whether that’s the normal turbulence of a developed tech and biotech economy or something more concerning.
In 2026, Medtronic has been handling more than just the Santa Rosa closure. The company announced the elimination of 81 jobs at its Northridge facility, where its diabetes device operations are based, in a WARN notice filed in California earlier this year. These layoffs occurred as Medtronic gets ready to separate its Diabetes division, which employs over 8,000 people worldwide, into MiniMed, a separate publicly traded business. The separation is anticipated to be finished by the end of this year, and the IPO filing was submitted at the end of 2025. The Northridge cuts, according to a Medtronic representative, are essential to providing MiniMed with the framework it needs to thrive as an independent business. It’s another matter entirely if 81 individuals found that framing to be consoling.
It’s difficult to ignore how frequently these announcements use the same terminology. “Align investments with long-term strategy.” “Focus on high-growth areas.” “Ensure the right structure.” The words barely show a seam as they move from one business press release to the next. Medtronic is not alone in this; in early 2026, businesses in the larger medtech industry, such as Baxter and Retractable Technologies, have been reducing staff and closing facilities due to changes in demand, tariff pressures, and the subtle logic of margin improvement. The industry-wide count for 2026 is already noteworthy, which begs the question of whether there is more going on than just standard restructuring.
The cuts don’t seem as shocking to Medtronic employees as they might seem from the outside, according to Reddit posts from both current and former workers. One commenter stated bluntly, “Medtronic layoffs happen every year-end,” characterizing the pattern as a persistent attempt to appease activist investors and maintain dividend stability. Another stated that competing medtech firms have created plans expressly to recruit Medtronic personnel during the regular post-layoff windows in May and June. A talent poaching calendar based on someone else’s yearly reorganization is strange to read, but it illustrates how institutionalized this has become both inside and outside of Medtronic.
The timeline and the specificity of what is being lost make the Santa Rosa closure feel more significant than a normal workforce adjustment. Those who developed automated reporting tools, oversaw international post-market studies, and cultivated close ties with doctors who use Medtronic devices in the field are among the positions being phased out. These are not reductions in the back office. The operations will be absorbed by the Galway, Ireland site, as well as Minneapolis and Santa Ana, but institutional knowledge rarely transfers as smoothly as an organizational chart indicates. In the end, Medtronic’s reorganization might put it in a better position to compete in the medical device industry for the next ten years. It’s also possible that some of the current cuts will be difficult to rebuild in the future.⁖※
